Neuroblastoma
What's New
Last Posted: Jul 28, 2023
- Clinical trio genome sequencing facilitates the interpretation of variants in cancer predisposition genes in paediatric tumour patients
C. Shroeder et al, EJHG, July 28, 2023 - Mathematical modeling of neuroblastoma associates evolutionary patterns with outcomes
G Caravagna, Nature Genetics, March 27, 2023 - Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up.
Elizabeth Schepke et al. Clinical epigenetics 2023 15(1) 40 - Germline pathogenic variants in 786 neuroblastoma patients.
Jung Kim et al. medRxiv : the preprint server for health sciences 2023 - Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology without MYCN Amplification.
Navin Pinto et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 - CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.
Tan Eelin et al. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2022 - Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto Tadashi et al. International journal of clinical oncology 2021 - The genomics and epigenetics of olfactory neuroblastoma: A systematic review.
Kaur Raman Preet et al. Laryngoscope investigative otolaryngology 2021 6(4) 721-728 - Differential Impact of ALK Mutations in Neuroblastoma.
O'Donohue Tara et al. JCO precision oncology 2021 5 - Development and Evaluation of a Leukemia Diagnosis System Using Deep Learning in Real Clinical Scenarios.
Zhou Min et al. Frontiers in pediatrics 2021 9693676 - The MicroRNA Landscape of MYCN-Amplified Neuroblastoma.
Misiak Danny et al. Frontiers in oncology 2021 11647737 - A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma.
Cimmino Flora et al. Frontiers in oncology 2020 10596191 - Metastatic Burden Defines Clinically and Biologically Distinct Subgroups of Stage 4 High-Risk Neuroblastoma.
Seo Eun Seop et al. Journal of clinical medicine 2020 Aug 9(9) - Genomic co-amplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso Loredana et al. Genes, chromosomes & cancer 2019 Nov - Tandem Transplant for High-Risk Neuroblastoma-Next Steps in the Era of Precision Medicine
R Bagatell, JAMA, August 27, 2019 - Tandem Transplant for High-Risk Neuroblastoma: Next Steps in the Era of Precision Medicine.
Bagatell Rochelle, et al. JAMA 2019 0 0. (8) 729-731 - Study reveals elevated cancer risk in children with birth defects,
EurekAlert, June 25, 2019 - The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to Progress
D Lowy, NCI Director Blog, June 12, 2019 - Distillation of the clinical algorithm improves prognosis by multi-task deep learning in high-risk Neuroblastoma.
Maggio Valerio et al. PloS one 2018 13(12) e0208924 - Molecularly Targeted Therapy for Neuroblastoma.
Greengard Emily G et al. Children (Basel, Switzerland) 2018 Oct 5(10)
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 18, 2024
- Content source: